The global in vitro fertilization (IVF) hormones market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2021-2029. The market is primarily driven by the lowering fertility rate worldwide, growing distress among the majority of couples for the incidences of infertility caused either by physiological or genetically arrived disorders, along with the increasing concerns for obesity and male infertility. According to the statistics by the World Bank, the fertility rate around the world decreased from 2.696 (births per woman) in the year 2000 to 2.415 in the year 2018.
In vitro fertilization (IVF) is referred to the process of human reproduction where eggs from a woman’s ovaries are harvested and then fertilized in an artificial setting, and later implanted back into the uterus of the woman. This form of assisted reproductive technology (ART) solves problems related to infertility among both men and women. IVF hormones are referred to the fertility drugs that are given to men to produce sperms in case of male factor infertility, and in women to boost egg production, which further helps the women to achieve pregnancy through the process of IVF. CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization (WHO), globally around 186 million individuals and 48 million couples live with infertility.
The global in vitro fertilization hormones market is thriving primarily on account of the growing demand for IVF procedures, which has spiked significantly in the last few years, backed by the increasing incidences of infertility and therefore the need amongst individuals to undergo an IVF procedure. IVF has emerged as a revolutionary technique that helps couples to have their own child y allowing the fertilization procedure outside the body. IVF hormones help to catalyze the process by stimulating the production of eggs or sperms in women and men respectively. The market is segmented by type into follicle-stimulating hormone (FSH)/gonadotropin-releasing hormone agonist (GnRH), and luteinizing hormone (LH). Among these segments, the follicle-stimulating hormone (FSH) segment is anticipated to hold the largest market share by the end of 2021. The growth of the segment can be attributed primarily to the ability of the hormone to stimulate the growth of the small follicles which increases the success rate of pregnancy through IVF, along with the high preference of the healthcare practitioners for the utilization of FSH.
According to the Centers for Disease Control and Prevention (CDC), PCOS is one of the most common causes of female infertility amongst the US women of reproductive age, affecting as many as 5 million individuals (6% to 12% of US women of reproductive age).
One of the major causes of infertility in women is due to the occurrence of polycystic ovary syndrome (PCOS), which is linked to being overweight or having a family history of type 2 diabetes or PCOS. Rising awareness for infertility treatment, owing to the increasing incidences of infertility, rising cases of PCOS, and the growing number of couples who defer childbearing, are some of the factors anticipated to drive the demand for the use of IVF hormones, and in turn, drive the market growth. Moreover, increasing advancements in the field of IVF treatments, along with the growing success rate of IVF treatments are some of the additional factors anticipated to drive the growth of the IVF hormones market in the coming years.
With numerous advantages associated with in vitro fertilization treatment procedures, there also lies numerous disadvantages, that are anticipated to hamper the market growth. One of the primary challenges associated with the growth of the market is the high cost of IVF treatment, which directly affects the demand for IVF hormones. Alternatively, the concern for risk of multiple births upon the use of these hormones, along with the severe reactions caused by the fertility drugs, such as ovarian hyperstimulation syndrome, and the social barriers present in several under-developed and developing nations for adopting IVF treatment, are some of the major factors anticipated to lower the market growth in the coming years.
Our in-depth analysis of the global in vitro fertilization (IVF) hormones market includes the following segments:
On the basis of regional analysis, the global in vitro fertilization (IVF) hormones market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa regions. Among these regions, the market in Europe is projected to witness the highest market share by the end of 2029, backed by the increasing adoption of IVF procedures amongst individuals, and the increasing support of the government for raising awareness for IVF treatments. According to the statistics by the Human Fertilisation & Embryology Authority (HFEA), in the year 2018, around 54000 patients had 5651 donor insemination (DI) cycles and 68724 fresh & frozen IVF cycles at fertility clinics licensed by the HFEA in the United Kingdom.
The global in vitro fertilization (IVF) hormones market is further classified on the basis of region as follows:
FREQUENTLY ASKED QUESTIONS
Increasing incidences of infertility worldwide, and the need amongst individuals to opt for IVF treatments, are some of the major factors driving the market growth.
The market is anticipated to grow with a moderate CAGR over the forecast period, i.e., 2021-2029.
The high cost of IVF treatment, health risks of taking IVF hormones are some of the major factors estimated to act as barriers to the growth of the market.
The major companies in the market are Merck KGaA (OTCMKTS: MKKGY), GENPHARM, Aquatic Group, BioVendor – Laboratorni medicina a.s., Biogenix Inc. Pvt. Ltd., and others.
The company profiles are selected based on the revenues generated from segments, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market in Europe is projected to witness the highest market share by the end of 2029 owing to the growing awareness of IVF treatment amongst the individuals.
The in vitro fertilization (IVF) hormones market is segmented by type, gender, and by region.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization